Kairos Pharma, Ltd. (KAPA)
NYSEAMERICAN: KAPA · Real-Time Price · USD
0.8110
+0.0260 (3.31%)
May 2, 2025, 10:44 AM EDT - Market open

Kairos Pharma Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2024 FY 2023 FY 2022 FY 2021
Period Ending
Dec '24 Dec '23 Dec '22 Dec '21
Selling, General & Admin
1.931.630.481.76
Research & Development
0.410.080.090.18
Operating Expenses
2.341.710.571.94
Operating Income
-2.34-1.71-0.57-1.94
Interest Expense
-0.19-0.1-0.46-0.16
Other Non Operating Income (Expenses)
-0.67--0.02-0.04
EBT Excluding Unusual Items
-3.2-1.81-1.05-2.15
Other Unusual Items
0.6---
Pretax Income
-2.6-1.81-1.05-2.15
Net Income
-2.6-1.81-1.05-2.15
Net Income to Common
-2.6-1.81-1.05-2.15
Shares Outstanding (Basic)
1110109
Shares Outstanding (Diluted)
1110109
Shares Change (YoY)
9.38%1.42%11.86%-
EPS (Basic)
-0.23-0.17-0.10-0.23
EPS (Diluted)
-0.23-0.17-0.10-0.23
EBITDA
-2.18-1.55-0.41-1.85
D&A For EBITDA
0.160.160.160.1
EBIT
-2.34-1.71-0.57-1.94
Updated Nov 14, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q